There are drugs that act on different mechanisms. One of them is supposedly going to act on intercellular protein aggregates, which has something in common with a number of neurodegenerative disorders. So it's a compound that works on that. That's from a small biotech company. There is something from another small biotech company that is working on the main system of cell death in motor neurons, which has been identified in the lab.
There are a few problems. Small biotech companies can only go so far because of their commercial reality. If something isn't snapped up by a large biotech company and individual clinical trial centres don't have funding--which they don't--this is the stuff that sort of sits by the wayside.